Last quarter (Q4 2023), Indaptus Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Indaptus Therapeutics's net income was $-4.00M. See Indaptus Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	-	-	-	-	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 7.47M	$ 16.38M	$ 14.91M	$ 7.73M	$ 3.60M
Operating Income	$ -7.47M	$ -16.38M	$ -14.91M	$ -7.73M	$ -3.60M
Net Non Operating Interest Income Expense	$ 201.93K	-	$ 588.11K	$ 17.72K	$ 15.11K
Other Income Expense	$ -623.85K	$ -955.00K	$ -96.43K	-	-
Pretax Income	$ -6.64M	$ -15.42M	$ -14.43M	$ -7.71M	$ -3.58M
Tax Provision	$ 13.92K	$ 13.92K	$ -73.37K	$ -44.33K	-
Earnings From Equity Interest Net Of Tax	$ -129.23K	-	-	-	-
Net Income Common Stockholders	$ -6.64M	$ -15.40M	$ -14.43M	$ -7.71M	$ -3.58M
Basic EPS	$ -1.84	$ -1.83	$ -1.73	$ -1.89	$ -0.66
Diluted EPS	$ -1.84	$ -1.83	$ -1.73	$ -1.89	$ -0.66
Basic Average Shares	$ 33.60M	$ 8.40M	$ 8.26M	$ 4.09M	$ 5.41M
Diluted Average Shares	$ 33.60M	$ 8.40M	$ 8.26M	$ 4.09M	$ 5.41M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 7.47M	$ 16.38M	$ 14.91M	$ 7.73M	$ 3.60M
Net Income From Continuing And Discontinued Operation	$ -15.40M	$ -15.40M	$ -14.32M	$ -7.71M	$ -3.58M
Normalized Income	$ -8.82M	$ -12.18M	-	-	$ -3.58M
Interest Expense	-	-	-	-	-
EBIT	$ -6.64M	$ -15.42M	$ -14.43M	$ -7.71M	$ -3.60M
EBITDA	$ -6.64M	$ -15.42M	$ -14.43M	$ -7.71M	$ -3.60M

Currency in USD

Indaptus Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing